Phase Ia/Ib Study Of RSC-1255 In Patients With Advanced Solid Tumor Malignancies, Including Pancreatic Cancer
The purpose of this phase Ia/Ib study is to evaluate the safety and efficacy of RSC-1255 in patients with advanced solid tumors, including pancreatic malignancies that are intolerant or has progressed after standard therapy, or have previously failed other therapies.
Study ID: RSC-101
Trial Phase: Phase I
Trial Sponsor: RasCal Therapeutics, Inc.
Therapies Used in This Trial: RSC-1255